Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4135 - Proteomic-based machine learning computational analysis discovered biomarkers of aberrant vesicle-exosomal trafficking to determine chemotherapeutic responses in breast cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

HanSuk Ryu

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

H. Ryu1, D.H. Han2, K. Lee3, K. Kim3

Author affiliations

  • 1 Pathology And Proteomics Core Facility, Seoul National University Hospital (SNUH)-Yongon Campus, 03080 - Seoul/KR
  • 2 Proteomics Core Facility, Seoul National University Hospital, 03080 - Seoul/KR
  • 3 Biomedical Research Institute, Seoul National University Hospital, 03080 - Seoul/KR
More

Resources

Abstract 4135

Background

The chemotherapeutic response is still low, and the need for a biomarker to overcome chemo-resistance is necessary.

Methods

We performed quantitative proteomics mass spectrometry in paired 20 FFPE biopsy breast cancer samples consist of non-responsive and responsive groups to chemotherapy. For verification of enriched biomarkers and biological pathways, ten human breast cancer cell lines enrolled and verified biological functions through molecular biology-driven assays, including RNAi, celltiter-glo luminescent assay, mitochondrial membrane potential assay (MMPA), IF, exosome uptake assay, time-lapse live cell imaging system, and the 3D tumor spheroid-based function assays. Machine learning analysis using r-caret recursive feature elimination to select and apply them to an independent cohort with 50 FFPE biopsy samples to discover the most optimal combination of immunohistochemical biomarkers to predict chemo-responsiveness.

Results

A total of 6,424 proteins were identified and 254 were confirmed to be significantly altered proteins related to chemotherapeutic response. From the patient group with chemo-resistance, we featured 56 upregulated proteins considerably in six closely related subcellular organelles concerning transcellular transportation system based on domain knowledge for text-mining and public network databases for network analysis. 14 intracellular exosomal transportation markers were identified to control chemo-sensitivity through siRNA array panel assay. Live cell images showed changed exosomal trafficking in cell lines manipulated by candidate markers. Through the verification step by machine learning analysis, we selected five markers and applied them to an independent cohort with FFPE biopsy samples to discover the most optimal combination of immunohistochemical biomarkers to predict chemo-responsiveness.

Conclusions

The present study provides the first evidence to identify a predictive biomarker for chemotherapeutic response based on in-depth proteomics. The newly discovered biomarkers and biological evidence can provide the novel insight to overcome chemoresistance in breast cancer.

Clinical trial identification

Legal entity responsible for the study

Han Suk Ryu.

Funding

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings